China Shineway Pharmaceutical Group Full Year 2024 Earnings: Misses Expectations

China Shineway Pharmaceutical Group (HKG:2877) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥3.78b (down 16% from FY 2023).
• Net income: CN¥840.1m (down 13% from FY 2023).
• Profit margin: 22% (in line with FY 2023).
• EPS: CN¥1.11 (down from CN¥1.28 in FY 2023).

2877 Products In Clinical Trials

• Phase III: 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Shineway Pharmaceutical Group Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) also missed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are down 11% from a week ago.

Risk Analysis

Be aware that China Shineway Pharmaceutical Group is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.